This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Effect of donepezil on emergence of apathy in mild to moderate Alzheimer’s disease


Waldemar, Gunhild, Gauthier, Serge, Jones, Roy, Wilkinson, David, Cummings, Jeffrey, Lopez, Oscar, Zhang, Richard, Xu, Yikang, Sun, Yijun, Nakano, Seigo, Richardson, Sharon, Mackell, Joan


International Journal Of Geriatric Psychiatry, Volume: 26, No.: 2, Pages.: 150-157

Year of Publication



Objective: To determine whether donepezil treatment (10 mg/day over 24 weeks) is associated with delayed emergence of apathy in patients with mild to moderate Alzheimer’s disease (AD) and to explore relationships between donepezil’s effects on apathy and other Neuropsychiatric Inventory (NPI)-measured behavioural symptoms.; Methods: Two randomised, double-blind, parallel-group, placebo-controlled studies that met prespecified criteria and were sufficiently similar to allow data pooling were derived from all donepezil AD clinical trials. Patients scoring from 10 to 26 on baseline Mini-Mental Status Examination were included. A clinical milestone for apathy and other NPI items was defined as the first emergence of a composite score (frequency × severity) ≥ 3. Differences in time to event (i.e. milestone) between donepezil- and placebo-treated groups were assessed using the Kaplan-Meier method and log-rank test. Shift tables were constructed to evaluate clinical milestone status for apathy and other NPI items at baseline and endpoint, and were analysed using the Cochran-Mantel-Haenszel (CMH) test, stratified by baseline status.; Results: Of all NPI items, apathy had the highest proportion of subjects scoring ≥ 3 at baseline. Donepezil was superior to placebo on both apathy milestone analyses (time-to-event log-rank test and shift table CMH test, p = 0.01). Aberrant motor behaviour demonstrated similar benefit.; Conclusions: Donepezil treatment appears to have resulted in a significant reduction over 6 months of the emergence of apathy in patients with AD. These data suggest that a prospective clinical trial in patients with early AD that includes apathy as a primary outcome measure may be warranted.; Copyright © 2010 John Wiley & Sons, Ltd.

Bibtex Citation

@article{Waldemar_2011, doi = {10.1002/gps.2507}, url = {}, year = 2011, month = {jan}, publisher = {Wiley-Blackwell}, volume = {26}, number = {2}, pages = {150--157}, author = {Gunhild Waldemar and Serge Gauthier and Roy Jones and David Wilkinson and Jeffrey Cummings and Oscar Lopez and Richard Zhang and Yikang Xu and Yijun Sun and Sean Knox and Sharon Richardson and Joan Mackell}, title = {Effect of donepezil on emergence of apathy in mild to moderate Alzheimer{textquotesingle}s disease}, journal = {Int. J. Geriat. Psychiatry} }